Celon Pharma First Quarter 2024 Earnings: zł0.31 loss per share (vs zł0.30 loss in 1Q 2023)

Celon Pharma (WSE:CLN) First Quarter 2024 Results

Key Financial Results

• Revenue: zł40.3m (down 7.5% from 1Q 2023).
• Net loss: zł15.7m (loss widened by 1.2% from 1Q 2023).
• zł0.31 loss per share (further deteriorated from zł0.30 loss in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Celon Pharma Earnings Insights

Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Poland.

The company's shares are down 6.3% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Celon Pharma's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.